Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for ...

The company was studying its therapy called rese-cel at the lowest dose without preconditioning in patients with pemphigus vulgaris. ・After discontinuing all immunomodulators, two of the four patients ...

Cabaletta Bio shares rose after the company said it is pricing an underwritten offering of about 51.7 million shares at $2.90 a share. Shares of the biotechnology company developing treatments for ...

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

US clinical-stage biotech Cabaletta Bio, which is developing and launching curative targeted cell therapies designed ...

Additional information, including the accepted abstracts, can be accessed on the website of the ASGCT 2026 Annual Meeting. Presentation materials will be made available on the Posters & Publications ...

– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development ...

Cabaletta Bio ( (CABA)) has provided an announcement. On May 4, 2026, Cabaletta Bio priced an underwritten registered direct offering of 51,725,000 shares of common stock at $2.90 per share, raising ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cabaletta Bio, Inc. (CABA) is a stock that can certainly grab the ...